Skip to main content
Fig. 4 | Journal of Innovation and Entrepreneurship

Fig. 4

From: A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates

Fig. 4

Comparison of rNPV models used in study when applied to real world revenue generating medical interventions. For three large revenue-generating medical interventions, rNPV modelling was performed using the 5 major simulation models of this study. Ramipril/Tritace (a), Reopro (b), and dapagliflozin(c) were used as examples, with real numbers indicated in the tables corresponding to rNPV values, as well as sales, COGS, pre-development profit, estimated cost to develop, and profit margin

Back to article page